Can a common allergy pill keep liver cancer from returning?
NCT ID NCT07734766
First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time
Summary
This trial investigates whether ebastine, a widely used allergy medication, can reduce the risk of liver cancer returning after surgery. The study enrolls people with a specific high-risk tumor feature called tumor budding. All participants will take ebastine daily for a year, and researchers will track how many remain cancer-free during that time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ebastine, an allergy medication that may also block cancer cell invasion
- What this could lead to
- If it works, this could point toward a simple, well-tolerated way to lower the chance of liver cancer coming back after surgery.
- What could go wrong
- This is a small, single-arm trial with no placebo group, so any benefit seen could be due to chance or other factors. Ebastine is not yet proven to fight cancer in humans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATO-CELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Artificial intelligence may help decide who gets a liver first
- AI may outsmart current system for liver transplant priority
- 3D MRI scan may predict liver cancer treatment success
- New scan could spot hidden cancer left behind after liver surgery
- Small study tests best way to mix chemo for liver tumors
- Can immunotherapy plus liver treatments open the door to transplants for more cancer patients?